Dear Cancer Center Faculty:

NCI recognizes that NCI-designated Cancer Centers have undertaken critically important research to investigate SARS-CoV-2, and they want to support you in these efforts.

**Johns Hopkins SKCCC has been asked to propose up to **two **important SARS-CoV-2 research projects that may have an immediate impact.** These projects may have already begun or be about to begin. NCI is particularly interested in:

- Clinical trials of novel or repurposed drugs (hydroxychloroquine, Remdesivir, anti-IL6 receptor antibodies, Leflunomide, etc.)
- Identification of neutralizing antibodies in serologic samples of SARS-CoV-2-infected patients
- Natural history of SARS-CoV-2 infection, including data collection and generation of aggregated data sets and analysis
- Natural history of SARS-CoV-2 in cancer patients (both those under active treatment and not) and the impact of the pandemic on clinical trial research and accrual
- Better methods of screening, detection, and prevention
- Novel approaches for community monitoring and care delivery (e.g., surveillance apps, telehealth, etc.) for cancer patients during this period
- Other ideas

These research projects do not need to be limited to cancer patients.

A team from NCI will evaluate for possible P30 supplemental funding (up to $250,000 direct cost per supplement). Please understand that NCI has limited funds available this late in the fiscal year.

If interested in being a part of this proposal, please email a 1-2 page proposal to Caitlin Campbell (ccampb52@jhmi.edu) by Thursday, March 26, 12pm noon EST.

Please note: biosketches, budgets, etc. are not needed at this time. Please simply send a half page, one page max, proposal.